Mustang Bio (Mustang Bio) EBIT : $-50.29 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Mustang Bio EBIT?

Mustang Bio's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-11.41 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-50.29 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mustang Bio's annualized ROC % for the quarter that ended in Dec. 2023 was -357.33%. Mustang Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -916.88%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Mustang Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3,947.25%.

Mustang Bio EBIT Historical Data

The historical data trend for Mustang Bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mustang Bio EBIT Chart

Mustang Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-44.62

-56.10

-66.36

-74.17

-50.29

Mustang Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-18.47	-15.52	-13.30	-10.05	-11.41

Competitive Comparison of Mustang Bio's EBIT

For the Biotechnology subindustry, Mustang Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mustang Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mustang Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mustang Bio's EV-to-EBIT falls into.

Mustang Bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.29 Mil.

Mustang Bio (NAS:MBIO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mustang Bio's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-35.424 * ( 1 - 0% )	/	( (10.073	+	9.754)	/ 2 )
=	-35.424	/	9.9135
=	-357.33 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	20.567	-	11.072	-	( 9.562	-	max(0, 14.166	-	13.588	+	9.562	))
=	10.073

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	17.742	-	12.013	-	( 6.234	-	max(0, 15.371	-	11.346	+	6.234	))
=	9.754

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Mustang Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-45.656	/	( ( (5.146 + max(-9.687, 0))	+	(4.813 + max(-13.618, 0)) )	/	2 )
=	-45.656	/	( ( 5.146	+	4.813 )	/	2 )
=	-45.656	/	4.9795
=	-916.88 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.026)	-	(11.072	+	0	+	2.641)
=	-9.687

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.233)	-	(12.013	+	0	+	2.838)
=	-13.618

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Mustang Bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-50.288	/	-1.274
	=	3,947.25 %

Mustang Bio EBIT Related Terms

Thank you for viewing the detailed overview of Mustang Bio's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Mustang Bio (Mustang Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mustang Bio Inc (NAS:MBIO) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

377 Plantation Street, Worcester, MA, USA, 01605

Website

https://www.mustangbio.com

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors.

Executives

Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Manuel Md Litchman	director, officer: President and CEO	2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10017
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Brian Achenbach	officer: SVP, Fin. & Corp. Controller	2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Adam J. Chill	director	24 NEW ENGLAND EXECUTIVE PARK, SUITE 105, BURLINGTON MA 01803
Michael S Weiss	director	750 LEXINGTON AVE, NEW YORK NY 10022
Michael J Zelefsky	director
David J Horin	officer: Interim CFO	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020